Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Adverse drug events related to polypharmacy in older adults: evaluating deprescribing opportunities in HIV patients through the MedSafer study
EF 2019-20
Résumé
"Polypharmacy, often defined as the concurrent use of five or more medications, is increasingly common in older adults aged 65-years and older. Physiological changes within the body at this age affect medication sensitivity and elimination and are compounded with an increase in age-related diseases. This makes older adults particularly vulnerable to adverse drug events (ADEs), which are an injury resulting from medical intervention related to a drug. While Polypharmacy may be well-intentioned for the treatment of chronic diseases, older adults may be prescribed potentially inappropriate medications (PIMs), which confer less benefit and expose them to harm. Several large clinical trials are underway to address this growing problem through deprescribing, which is the deliberate action of carefully stopping PIMs in a supervised setting. We aim to expand this research to the HIV population, where older adults are defined as 50 years or older. Due to the success of antiretroviral therapy, the lifespan of people living with HIV is increasing, posing new challenges for physicians as they are more likely to have multiple complicated illnesses and polypharmacy at a younger age. In this case, polypharmacy is defined as the concurrent use of 5 or more non-antiretroviral medications. We aim to quantify the need of a deprescribing intervention in this complex aging population. Patient data will be inputted into the novel Canadian deprescribing software, MedSafer, which will flag PIMs and allow us to describe the prevalence and most common PIMs seen. This research is the initial step to inform the need for a deprescribing intervention in the outpatient HIV clinic, and to prevent future ADEs and life-threatening complications."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
429060
Name
Ross Sydney B
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Adverse drug events related to polypharmacy in older adults: evaluating deprescribing opportunities in HIV patients through the MedSafer study
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adverse Drug Events (Ades); Deprescribing; Hiv; Medsafer; Polypharmacy; Potentially Inappropriate Medications (Pims)
Abstract
"Polypharmacy, often defined as the concurrent use of five or more medications, is increasingly common in older adults aged 65-years and older. Physiological changes within the body at this age affect medication sensitivity and elimination and are compounded with an increase in age-related diseases. This makes older adults particularly vulnerable to adverse drug events (ADEs), which are an injury resulting from medical intervention related to a drug. While Polypharmacy may be well-intentioned for the treatment of chronic diseases, older adults may be prescribed potentially inappropriate medications (PIMs), which confer less benefit and expose them to harm. Several large clinical trials are underway to address this growing problem through deprescribing, which is the deliberate action of carefully stopping PIMs in a supervised setting. We aim to expand this research to the HIV population, where older adults are defined as 50 years or older. Due to the success of antiretroviral therapy, the lifespan of people living with HIV is increasing, posing new challenges for physicians as they are more likely to have multiple complicated illnesses and polypharmacy at a younger age. In this case, polypharmacy is defined as the concurrent use of 5 or more non-antiretroviral medications. We aim to quantify the need of a deprescribing intervention in this complex aging population. Patient data will be inputted into the novel Canadian deprescribing software, MedSafer, which will flag PIMs and allow us to describe the prevalence and most common PIMs seen. This research is the initial step to inform the need for a deprescribing intervention in the outpatient HIV clinic, and to prevent future ADEs and life-threatening complications."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ross, Sydney B
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~